Alzheimer's drug LEQEMBI under 6-Year safety watch in 3,000 patients
NCT ID NCT06810960
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will follow 3,000 South Korean Alzheimer's patients taking LEQEMBI for up to 6 years to monitor safety, especially brain swelling or bleeding. Researchers will use real-world data from a national registry. The goal is to understand how often these side effects occur in everyday medical practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Eisai Trial Site #1
RECRUITINGNutley, New Jersey, 07110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could your brain help unlock Alzheimer's secrets?
- Can a gene therapy clear the toxic tau tangle in Alzheimer's?
- Can a new drug tame Alzheimer's? early trial aims to find out
- A scan that sees Alzheimer's tangles? trial puts tau tracer to the test
- Can a pill clear the toxic proteins behind Alzheimer's?
- A light switch for better sleep? Alzheimer's trial tests wireless circadian lighting